News
Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...
EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.
TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...
Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...
Key points Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show striking effectiveness across diverse populations at high risk for HIV.
Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...
The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...
The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.
Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results